Compare Quest Diagnostics Inc (DGX) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs EPAM Systems Inc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while EPAM Systems Inc trades at $85.52 (market cap $4.41B). The key difference: Quest Diagnostics Inc is far larger — about 5.2× EPAM Systems Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| DGX | EPAM | |
|---|---|---|
Market Cap | $22.80B | $4.41B |
Sector | Health | Technology |
52-Week High | $216.02 | $221.40 |
52-Week Low | $166.42 | $76.04 |
Enterprise Value | $28.82B | $3.67B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EPAM trades at $86.38, up 2.97% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 12.41 and P/S of 0.86, supported by consistent earnings beats in recent quarters. Revenue grew to $5.46B in 2025, though net income margin dipped to 6.96%. Recent news highlights EPAM's AI partnerships and upcoming Q2 earnings, with analyst sentiment strongly bullish.
The outlook for EPAM is positive given its low valuation multiples and strong analyst consensus, with a price target of $128.55 implying significant upside. Risks include competitive pressures in IT services and potential margin compression, but the company's focus on AI transformation and solid cash flow generation provide a foundation for growth. Investors should weigh the high institutional confidence against macroeconomic headwinds affecting the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
